TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7797785

Group type: EXPERIMENTAL
Intervention: 800 micrograms of inhaled triamcinolone once daily at 3:00 PM (QD group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 200 micrograms of inhaled triamcinolone four times a day (QID group)
Number of subjects: 0
Study: 2187604

Group type: EXPERIMENTAL
Intervention: Rice ORS
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Glucose ORS
Number of subjects: 2000

Group type: COMPARATOR
Intervention: No ORS (comparison group)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Staple-based ORS
Number of subjects: 2000
Study: 30539694

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 28456619

Group type: EXPERIMENTAL
Intervention: Well-controlled weeks (WCWs)
Number of subjects: 620
Study: 26409223

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study: 23131574

Group type: EXPERIMENTAL
Intervention: Nonprotein calorie (NPC) supplement (200-kcal daily)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Dietary counseling only (control group)
Number of subjects: 109
Study: 21439167

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Supralingual immunotherapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both SLIT and supralingual immunotherapy
Number of subjects: 51
Study: 20032907

Group type: EXPERIMENTAL
Intervention: modified constraint-induced movement therapy (mCIT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: conventional physiotherapy
Number of subjects: 10
Study: 16478570

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg daily for the first week, then 10 mg for 11 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15054369

Group type: EXPERIMENTAL
Intervention: Radiofrequency volumetric tissue reduction (RFVTR)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 11327520

Group type: EXPERIMENTAL
Intervention: homeopathically prepared mercury 12C
Number of subjects: 104

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 104
Study: 9159420

Group type: COMPARATOR
Intervention: CPA 2 mg with 35 microg of ethinylestradiol for 21 days each month (Diane group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CPA 50 mg, days 5‐15, and ethinylestradiol 50 microg, days 5‐25, each month (CPA group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Decapeptyl 3.75 mg i.m. every 28 days with conjugated oestrogen 0.625 mg, days 1‐21, and medroxyprogesterone acetate 10 mg, days 12‐21 (GnRHa group)
Number of subjects: 60
Study: 8187240

Group type: EXPERIMENTAL
Intervention: LDL-apheresis
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: LDL-apheresis combined with Pravastatin and Niceritrol
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: LDL-apheresis combined with lipid-lowering drugs
Number of subjects: 54
Study: 3285254

Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31942927

Group type: EXPERIMENTAL
Intervention: Inulin-type fructans (ITFs) treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (placebo) treatment
Number of subjects: 21
Study: 31051259

Group type: EXPERIMENTAL
Intervention: NO3− supplementation with NO3−‐rich beetroot juice
Number of subjects: 11
Study: 27856385

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 64

Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 64
Study: 25263735

Group type: EXPERIMENTAL
Intervention: Early placement (Ea)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Delayed placement (De)
Number of subjects: 44
Study: 23352054

Group type: EXPERIMENTAL
Intervention: Preoperative transfusion
Number of subjects: 70

Group type: COMPARATOR
Intervention: No preoperative transfusion
Number of subjects: 70
Study: 21856267

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg, BID), amoxicillin (1000 mg, BID), clarithromycin (500 mg, BID) for 14 days, plus vitamin C (500 mg, BID) and vitamin E (200 IU, BID) for 30 days (Group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lansoprazole (30 mg, BID), amoxicillin (1000 mg, BID), clarithromycin (500 mg, BID) for 14 days (Group B)
Number of subjects: 120
Study: 17631400

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day
Number of subjects: 395

Group type: COMPARATOR
Intervention: Pregabalin 150 mg/day
Number of subjects: 395

Group type: COMPARATOR
Intervention: Pregabalin 300 mg/day
Number of subjects: 395

Group type: COMPARATOR
Intervention: Pregabalin 150, 300, and 600 mg/day
Number of subjects: 395
Study: 16543744

Group type: EXPERIMENTAL
Intervention: Intranasal (IN) diamorphine spray
Number of subjects: 4

Group type: COMPARATOR
Intervention: Intravenous (IV) diamorphine
Number of subjects: 4
Study: 14643039

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Naproxen sodium 550 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 11054329

Group type: EXPERIMENTAL
Intervention: Multifocal IOL
Number of subjects: 245

Group type: COMPARATOR
Intervention: Monofocal IOL
Number of subjects: 245
Study: 8610901

Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol 2 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol 1 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acetaminophen 600 mg and codeine 60 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1427925

Group type: EXPERIMENTAL
Intervention: Antegrade cardioplegia and reperfusion (Group I, 80 patients)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Antegrade and retrograde cardioplegia with antegrade reperfusion (Group II, 98 patients)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Antegrade and retrograde cardioplegia with retrograde reperfusion (Group III, 88 patients)
Number of subjects: 266
Study: 3883822

Group type: EXPERIMENTAL
Intervention: Whole gut irrigation alone
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Whole gut irrigation + metronidazole
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Whole gut irrigation + metronidazole + ampicillin
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control (no whole gut irrigation)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Whole gut irrigation (clean bowel)
Number of subjects: 148
Study: 31386636

Group type: EXPERIMENTAL
Intervention: Glycated hemoglobin (HbA1c)
Number of subjects: 376644

Group type: EXPERIMENTAL
Intervention: Glycated hemoglobin (HbA1c) after excluding potentially invalid SNPs
Number of subjects: 376644
Study: 30365263

Group type: EXPERIMENTAL
Intervention: Acupuncture plus moxibustion
Number of subjects: 58

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 58
Study: 26634642

Group type: EXPERIMENTAL
Intervention: RCT-18 (180 mg, once weekly for 4 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 26179672

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (80 mg)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 212
Study: 23868016

Group type: EXPERIMENTAL
Intervention: Depression treatment completion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Barriers to treatment
Number of subjects: 30
Study: 21172497

Group type: EXPERIMENTAL
Intervention: Real-time three-dimensional echocardiography (RT3DE)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Two-dimensional echocardiography
Number of subjects: 52
Study: 19088351

Group type: EXPERIMENTAL
Intervention: Guideline ICUs
Number of subjects: 1118

Group type: COMPARATOR
Intervention: Control ICUs
Number of subjects: 1118
Study: 16564209

Group type: EXPERIMENTAL
Intervention: Hydrotherapy (HT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional physiotherapy (CP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hydrotherapy (HT) and Conventional physiotherapy (CP)
Number of subjects: 50
Study: 15192622

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy for 30 months
Number of subjects: 17

Group type: COMPARATOR
Intervention: Coenzyme Q(10) for 1 year
Number of subjects: 17
Study: 11084173

Group type: EXPERIMENTAL
Intervention: 200 microg vaginal misoprostol
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 9136529

Group type: EXPERIMENTAL
Intervention: Gelseal graft
Number of subjects: 44

Group type: COMPARATOR
Intervention: Hemashield graft
Number of subjects: 44
Study: 8151187

Group type: EXPERIMENTAL
Intervention: BCG 0.05 mg + 6 x 10(8) KML
Number of subjects: 860

Group type: COMPARATOR
Intervention: Normal saline (i.v.)
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: BCG 0.05 mg + 5 x 10(7) KML
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: BCG 0.01 mg + 5 x 10(7) KML
Number of subjects: 860
Study: 3731087

Group type: EXPERIMENTAL
Intervention: Cytarabine 2 g/m2/72 h by continuous infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytarabine 6 g/m2/72 h by continuous infusion
Number of subjects: 0
Study: 29808043

Group type: EXPERIMENTAL
Intervention: Low glycaemic index diet for 12 weeks
Number of subjects: 74
Study: 26885785

Group type: EXPERIMENTAL
Intervention: clin 1.0%-BP 3.75% gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: adap 0.1%-BP 2.5% gel
Number of subjects: 0
Study: 24530883

Group type: EXPERIMENTAL
Intervention: Creatine supplementation with resistance training (CR+RT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Creatine (CR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 60
Study: 22960587

Group type: EXPERIMENTAL
Intervention: TEENCOPE (Internet coping skills training)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Managing Diabetes (Internet educational intervention)
Number of subjects: 320
Study: 20473995

Group type: EXPERIMENTAL
Intervention: Abdominal ultrasonography screening
Number of subjects: 12639

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 12639
Study: 18838564

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 3261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3261

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 3261
Study: 15947765

Group type: EXPERIMENTAL
Intervention: Magnitude of cyclic variation (CV) of myocardial integrated backscatter (IBS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Normalized time delay (NTD)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: NTD greater than 1.35 as the optimal cutoff
Number of subjects: 80
Study: 11683668

Group type: EXPERIMENTAL
Intervention: Resistance 1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Resistance 2
Number of subjects: 10
Study: 9401251

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg daily, 20 mg during diarrhea)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study: 8429445

Group type: EXPERIMENTAL
Intervention: Modified bovine lung surfactant extract (beractant), 4 doses administered.
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (equal volume of air administered).
Number of subjects: 56
Study: 2887614

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine at night
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study: 29614274

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups (0.25% bupivacaine and normal saline)
Number of subjects: 51
Study: 26834240

Group type: EXPERIMENTAL
Intervention: 2 cycles of ABVD (2×ABVD; n = 137)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: 2 cycles of AVD (2×AVD; n = 82)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: 4 cycles of ABVD (4×ABVD; n = 68)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: 2 cycles of ABVD/AVD
Number of subjects: 287
Study: 23426565

Group type: EXPERIMENTAL
Intervention: Home-based exercise programme (n = 13)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Usual care (Control group, n = 12)
Number of subjects: 25
Study: 20720400

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention in primary care setting
Number of subjects: 4009
Study: 20037567

Group type: EXPERIMENTAL
Intervention: milgamma in combination with diclofenac
Number of subjects: 38

Group type: COMPARATOR
Intervention: diclofenac only
Number of subjects: 38
Study: 16810105

Group type: EXPERIMENTAL
Intervention: CytoFab (250 units/kg loading dose, followed by 50 units/kg every 12 hrs for 9 doses)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: CytoFab
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (5 mg/kg human albumin)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 12830736

Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplantation (HCT)
Number of subjects: 0
Study: 11061539

Group type: EXPERIMENTAL
Intervention: GH treatment with 6 IU/m2 body surface/day
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: GH treatment with 3 IU/m2 body surface/day
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: GH treatment (both dosages)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: GH treatment in GHD children
Number of subjects: 79

Group type: COMPARATOR
Intervention: Untreated children with short stature born SGA
Number of subjects: 79
Study: 9246281

Group type: EXPERIMENTAL
Intervention: Topical diclofenac
Number of subjects: 40
Study: 8299405

Group type: EXPERIMENTAL
Intervention: 3 g EDTA per infusion over a period of 5‐9 weeks to a total of 57 g EDTA
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 29
Study: 2852945

Group type: EXPERIMENTAL
Intervention: Retinol palmitate (300,000 I.U. daily)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control (no retinol palmitate)
Number of subjects: 181
Study: 29405231

Group type: EXPERIMENTAL
Intervention: 6-month care management intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 32
Study: 28800753

Group type: EXPERIMENTAL
Intervention: Universal prevention program (6 school hours)
Number of subjects: 2342

Group type: COMPARATOR
Intervention: No treatment control condition
Number of subjects: 2342
Study: 25681001

Group type: EXPERIMENTAL
Intervention: sub-Bowman keratomileusis (100-μm flap)
Number of subjects: 100

Group type: COMPARATOR
Intervention: laser in situ keratomileusis (LASIK) (120-μm flap)
Number of subjects: 100
Study: 23800004

Group type: COMPARATOR
Intervention: Nellcor pulse oximeter (PO)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Masimo pulse oximeter (PO)
Number of subjects: 44
Study: 20056851

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 3

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 3
Study: 18203048

Group type: EXPERIMENTAL
Intervention: Amisulpride 600 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Amisulpride 400 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Clozapine and placebo
Number of subjects: 16
Study: 20717044

Group type: EXPERIMENTAL
Intervention: Valdecoxib (20 mg intravenous)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN patch 10 mg/h)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Valdecoxib
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: GTN
Number of subjects: 380
Study: 16009103

Group type: EXPERIMENTAL
Intervention: Jianpi Qinghua Recipe (JPQHR) combined with routine therapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Routine therapy
Number of subjects: 106
Study: 12632840

Group type: EXPERIMENTAL
Intervention: 40 mg pravastatin per day
Number of subjects: 5804

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 5804
Study: 9785773

Group type: EXPERIMENTAL
Intervention: Combination of preventive measures for soccer and running injuries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic ankle stabilisers and/or proprioceptive ankle disc training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knee brace
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proprioceptive training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stretching, taping, mental training, controlled rehabilitation
Number of subjects: 0
Study: 7974685

Group type: EXPERIMENTAL
Intervention: Ivermectin, 150‐200 micrograms/kg in a single dose
Number of subjects: 60

Group type: COMPARATOR
Intervention: Albendazole, 400 mg/d for 3 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ivermectin, 150‐200 micrograms/kg in a single dose (second treatment course)
Number of subjects: 60
Study: 3141982

Group type: EXPERIMENTAL
Intervention: 5 weekly fractions of 2 Gy without any prior laparotomy
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: 3 weekly fractions of 3.3 Gy after laparotomy
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: 4 x 2.5 Gy
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: 5 x 2 Gy
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: 3 x 3.3 Gy
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Patients with previous laparotomy
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Patients without previous abdominal surgery
Number of subjects: 516
Study: 30061240

Group type: EXPERIMENTAL
Intervention: dMMR/met+
Number of subjects: 134

Group type: COMPARATOR
Intervention: pMMR/met+
Number of subjects: 134

Group type: COMPARATOR
Intervention: dMMR/met-
Number of subjects: 134

Group type: COMPARATOR
Intervention: pMMR/met-
Number of subjects: 134
Study: 26154086

Group type: EXPERIMENTAL
Intervention: Acarbose (12 mg/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Trans‐chalcone (12 mg/kg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Grape seed oil (control for trans‐chalcone)
Number of subjects: 48
Study: 23034474

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000 IU/d)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 21121175

Group type: EXPERIMENTAL
Intervention: Amantadine (100 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 18430910

Group type: COMPARATOR
Intervention: Mitomycin-based treatment (n = 341): fluorouracil (1000 mg/m2 on days 1-4 and 29-32) + mitomycin (10 mg/m2 on days 1 and 29) + radiotherapy (45-59 Gy)
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Cisplatin-based treatment (n = 341): fluorouracil (1000 mg/m2 on days 1-4, 29-32, 57-60, and 85-88) + cisplatin (75 mg/m2 on days 1, 29, 57, and 85) + radiotherapy (45-59 Gy; start day = day 57)
Number of subjects: 682
Study: 17003663

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (FLV)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Pill placebo (PBO)
Number of subjects: 128
Study: 14581268

Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery and radiotherapy
Number of subjects: 179

Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery
Number of subjects: 179
Study: 10812869

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8865702

Group type: EXPERIMENTAL
Intervention: Inhalation anesthesia (GOI)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Fentanyl (GOI + fentanyl 4.8 +/- 0.9 micrograms . kg‐1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Epidural (GOI + continuous epidural infusion 1.5% lidocaine, 5 ml . h‐1)
Number of subjects: 28
Study: 1371291

Group type: EXPERIMENTAL
Intervention: Finasteride (1, 5, 10, 50, or 100 mg/day for 7 days)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Finasteride (various doses)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Finasteride (2 days treatment)
Number of subjects: 69
Study: 6653057

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg orally at bedtime for four days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oxtriphylline 200 mg (equivalent to theophylline 135 mg) orally every eight hours for 10 doses
Number of subjects: 10
Study: 29611316

Group type: EXPERIMENTAL
Intervention: Medical clowns (MCs)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control (technician)
Number of subjects: 140
Study: 27339398

Group type: EXPERIMENTAL
Intervention: One-time BM-MSC transplantation (5 × 10^7 BM-MSCs)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Two-time BM-MSC transplantation (5 × 10^7 BM-MSCs)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: One-time BM-MSC transplantation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Two-time BM-MSC transplantation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 24624390

Group type: EXPERIMENTAL
Intervention: Full-mouth ultrasonic debridement followed by monthly supportive periodontal therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Full-mouth ultrasonic debridement followed by supportive periodontal therapy at 3-month intervals
Number of subjects: 28
Study: 22156722

Group type: EXPERIMENTAL
Intervention: Complex PTSD patients
Number of subjects: 49

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 49
Study: 19962354

Group type: EXPERIMENTAL
Intervention: Oxycodone 10 mg/day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Pregabalin (75, 150, 300, and 600 mg/day)
Number of subjects: 62
Study: 18953194

Group type: EXPERIMENTAL
Intervention: Workshop intervention consisting of discussions, didactic information, individual plan formulation, and strategies to cope with moral distress.
Number of subjects: 0
Study: 16914210

Group type: EXPERIMENTAL
Intervention: Acetaminophen plus honey
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 60
Study: 15165934

Group type: EXPERIMENTAL
Intervention: losartan 100 mg/day
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: irbesartan 300 mg/day
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: candesartan 16 mg/day
Number of subjects: 122

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 122